Research

Hormonal

Tirzepatide treatment duration is positively correlated with cumulative cardio-metabolic-kidney (CKM) benefits, with patients persisting on therapy for >1 year achieving significantly greater weight loss, lipid improvements, and hepatic/renal marker reductions compared to short-term users.

If you are using tirzepatide for obesity, sticking with it beyond the first year is critical. The data shows that patients who persist for more than a year lose significantly more weight and see greater improvements in heart, liver, and kidney markers than those who stop early. To maximize these benefits, work with your provider to manage side effects and ensure you have the support and resources to stay on the medication long-term.

ModerateSupportsMEDIUM confidence
Tirzepatide showed greater cumulative benefits across CKM syndrome outcomes during the second treatment year, highlighting the need to overcome adherence barriers in real-world settings.
Imran Rashid Rangraze et al. · Diabetes Therapy · 2026

Why this rating

Single-center observational cohort study with a modest sample size (n=100), subject to selection bias and lack of systematic adherence monitoring.

Source

Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates

Imran Rashid Rangraze et al. · Diabetes Therapy · 2026

DOI 10.1007/s13300-026-01868-2

cohort · n=100
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →